Quantification of ADCP Activity of Therapeutic Antibodies Using Engineered Effector Cells and Target Cells

Many therapeutic antibodies use antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) as key mechanisms of action.

Traditional methods for quantifying ADCP activity are labor-intensive and have a high level of inherent variability due to the use of primary human cells from different donors.

Here, we present a method for quantifying ADCP activity based on a novel iLite® effector cell and three genetically engineered target cells expressing a constant high level of the surface antigens CD20, HER2, or mTNF, as well as their antigen-negative counterparts.

Furthermore, by comparing our iLite ADCP assays to ADCP bioassays from a leading competitor, we found that the iLite ADCP assays offer a significantly improved dynamic range, while at the same time offering excellent sensitivity.

The iLite effector cell line with the specific target cells and the corresponding negative control cells are well suited for use in potency assays in a CMC environment or the quantification of ADCP activity and the anti-Fc humoral response in pre-clinical or clinical studies.